 |
Printer Friendly
Printed from http://www.researchandmarkets.com/reports/1317
Antibacterial Drug Licensing Opportunities: Analysis, Rating, and Ranking - A Worldwide Study
|
Description: |
This report is designed to provide a useful tool to professionals in research and development (R&D), marketing, business development, licensing, and strategic planning who are involved, or are anticipating involvement, in the discovery, development, licensing, and/or marketing of therapeutics and prophylactics for the treatment of bacterial infections. |
|
Contents: |
Antibacterial Drug Licensing Opportunities
SUMMARY TABLE OF CONTENTS
EXECUTIVE SUMMARY......................................................................................................................................... i
Section 1 INTRODUCTION TO ANTIBACTERIALS........................................................................................... 1
1.1 SCOPE AND OBJECTIVES OF RESEARCH INVESTIGATION........................................................... 1
1.2 METHODOLOGY OF INVESTIGATION................................................................................................ 1
1.3 LIMITATIONS OF INVESTIGATION ..................................................................................................... 2
1.4 INTRODUCTION TO BACTERIAL INFECTIONS AND THEIR THERAPY ....................................... 3
1.4.1 Introduction to Bacteria and Bacterial Infections............................................................................ 3
1.4.2 Bacterial Groups .............................................................................................................................. 4
1.5 GLOSSARY OF TERMS ......................................................................................................................... 12
Section 2 DELPHI PANEL AND THOUGHT LEADER INTERVIEW: DISCUSSION AND SUMMARY OF
ANTIBACTERIAL THERAPEUTICS INNOVATION........................................................... 17
2.1 INTRODUCTION .................................................................................................................................... 17
2.2 RESULTS OF DELPHI PANEL INTERVIEWS..................................................................................... 17
2.3 DELPHI SUMMARY............................................................................................................................... 33
Section 3 BACTERIAL INFECTIONS BY THERAPEUTIC AREA.................................................................. 35
3.1 RESPIRATORY TRACT INFECTIONS ................................................................................................. 35
3.1.1 Diseases Involved ........................................................................................................................... 35
3.1.2 Current and Likely Future Treatments........................................................................................... 36
3.1.3 Market Analysis............................................................................................................................. 37
3.2 GENITOURINARY TRACT INFECTIONS ........................................................................................... 40
3.2.1 Diseases Involved ........................................................................................................................... 40
3.2.2 Current and Likely Future Treatments........................................................................................... 40
3.2.3 Market Analysis............................................................................................................................. 41
3.3 GASTROINTESTINAL TRACT INFECTIONS ..................................................................................... 43
3.3.1 Diseases Involved ........................................................................................................................... 43
3.3.2 Current and Likely Future Treatments........................................................................................... 44
3.3.3 Market Analysis............................................................................................................................. 45
3.4 SKIN AND SOFT TISSUE INFECTIONS .............................................................................................. 47
3.4.1 Diseases Involved ........................................................................................................................... 47
3.4.2 Current and Likely Future Treatments........................................................................................... 47
3.4.3 Market Analysis............................................................................................................................. 47
3.5 OTHER INFECTIONS............................................................................................................................. 50
3.5.1 Central Nervous System Infections................................................................................................. 50
3.5.2 Intra-abdominal infections ............................................................................................................. 51
3.5.3 Ear infections ................................................................................................................................ 51
3.5.4 Bacteremia and Septicemia ............................................................................................................ 51
3.5.5 Bone and Joint Infections ............................................................................................................... 51
3.5.6 Stomatological Infections ............................................................................................................... 51
Section 4 ANTIBIOTICS......................................................................................................................................... 53
4.1 INTRODUCTION TO ANTIBIOTICS .................................................................................................... 53
4.2 MECHANISMS OF ANTIBIOTIC ACTION .......................................................................................... 53
4.2.1 Inhibition of Cell Wall Synthesis .................................................................................................... 53
4.2.2 Disruption of Cell Membrane Structure......................................................................................... 53
ii
4.2.3 Inhibition of Protein Synthesis ....................................................................................................... 54
4.2.4 Inhibition of DNA Transcription .................................................................................................... 54
4.3 CLASSES OF ANTIBIOTICS.................................................................................................................. 54
4.3.1 Penicillins, Cephalosporins, and Other Beta-Lactams .................................................................. 54
4.3.2 Aminoglycosides............................................................................................................................ 57
4.3.3 Tetracyclines ................................................................................................................................. 59
4.3.4 Macrolides..................................................................................................................................... 61
4.3.5 Streptogramins ............................................................................................................................... 63
4.3.6 Rifamycins ..................................................................................................................................... 65
4.3.7 Glycopeptides and Other Peptide Antibiotics................................................................................. 65
4.3.8 Quinolones .................................................................................................................................... 69
4.3.9 Oxazolidinones ............................................................................................................................... 74
4.3.10 Other Antibiotics ............................................................................................................................ 75
4.4 MECHANISMS OF ANTIBIOTIC RESISTANCE ................................................................................. 76
4.4.1 Antibiotic Inactivation................................................................................................................... 76
4.4.2 Antibiotic Entry and Efflux............................................................................................................. 76
4.4.3 Mutation of the Antibiotic Target Site ............................................................................................ 76
4.4.4 Alternative Metabolic Pathways..................................................................................................... 77
Section 5 TECHNOLOGY PLATFORMS OTHER THAN ANTIBIOTICS...................................................... 79
5.1 OTHER LOW-MOLECULAR-WEIGHT THERAPEUTICS.................................................................. 79
5.1.1 Trimethoprim and Sulfonamides .................................................................................................... 79
5.1.2 Metronidazole................................................................................................................................ 80
5.1.3 Nitrofurantoin and Other Nitrofurans............................................................................................ 80
5.2 VACCINES AND IMMUNOTHERAPIES.............................................................................................. 80
5.2.1 Vaccines ........................................................................................................................................ 80
5.2.2 Antibodies...................................................................................................................................... 86
5.2.3 Other Immunotherapies................................................................................................................. 87
5.3 OTHER TECHNOLOGIES...................................................................................................................... 88
Section 6 OVERALL ANALYSIS AND FORECAST FOR ANTIBACTERIALS ............................................. 89
6.1 PRODUCT TECHNOLOGY ANALYSIS AND FORECAST ................................................................ 89
6.2 MARKET ANALYSIS AND FORECAST ............................................................................................ 104
6.3 EVALUATION OF LICENSING OPPORTUNITIES – RATINGS AND RANKINGS....................... 107
Section 7 COMPANY PROFILES OF INNOVATIVE FIRMS REPRESENTING ACQUISITIONS,
LICENSING, AND COMARKETING OPPORTUNITIES IN antiBACTERIAL THERAPY
..................................................................................................................................................... 121
7.1 ACAMBIS .............................................................................................................................................. 121
7.2 ANTEX BIOLOGICS............................................................................................................................. 122
7.3 ANTIGENICS......................................................................................................................................... 122
7.4 AVANT IMMUNOTHERAPEUTICS ................................................................................................... 123
7.5 AXCAN PHARMA ................................................................................................................................ 123
7.6 CSL ...................................................................................................................................................... 124
7.7 CUBIST PHARMACEUTICALS........................................................................................................... 124
7.8 DAIICHI SEIYAKU............................................................................................................................... 125
7.9 DEMEGEN............................................................................................................................................. 126
7.10 ESSENTIAL THERAPEUTICS............................................................................................................. 126
7.11 GENOME THERAPEUTICS ................................................................................................................. 127
7.12 ID BIOMEDICAL CORPORATION ..................................................................................................... 127
7.13 INCYTE GENOMICS ............................................................................................................................ 128
7.14 INTERMUNE......................................................................................................................................... 129
7.15 INTRABIOTICS..................................................................................................................................... 130
7.16 LIGOCYTE PHARMACEUTICALS..................................................................................................... 130
7.17 MEDIMMUNE....................................................................................................................................... 131
7.18 MEIJI SEIKA.......................................................................................................................................... 131
iii
7.19 MICROLOGIX BIOTECH..................................................................................................................... 132
7.20 NABI ...................................................................................................................................................... 132
7.21 NEOSE TECHNOLOGIES .................................................................................................................... 133
7.22 NEWBIOTICS........................................................................................................................................ 133
7.23 NIPPON MEDICAL RESEARCH ......................................................................................................... 134
7.24 POWDERJECT PHARMACEUTICALS............................................................................................... 134
7.25 SEQUELLA............................................................................................................................................ 134
7.26 SHIONOGI ............................................................................................................................................. 135
7.27 SHIRE PHARMACEUTICALS GROUP............................................................................................... 136
7.28 SIGA TECHNOLOGIES........................................................................................................................ 136
7.29 TAIHO PHARMACEUTICAL COMPANY.......................................................................................... 137
7.30 TAKEDA CHEMICAL INDUSTRIES .................................................................................................. 137
7.31 TOYAMA CHEMICAL CO................................................................................................................... 137
7.32 VERSICOR............................................................................................................................................. 138
7.33 VICAL .................................................................................................................................................... 138
7.34 WAKUNAGA PHARMACEUTICAL CO............................................................................................. 139
7.35 XOMA .................................................................................................................................................... 139
iv
Antibacterial Drug Licensing Opportunities
DETAILED TABLE OF CONTENTS
EXECUTIVE SUMMARY................................................................................................................................................i
Section 1 INTRODUCTION TO ANTIBACTERIALS........................................................................................... 1
1.1 SCOPE AND OBJECTIVES OF RESEARCH INVESTIGATION........................................................... 1
1.2 METHODOLOGY OF INVESTIGATION................................................................................................ 1
1.3 LIMITATIONS OF INVESTIGATION ..................................................................................................... 2
1.4 INTRODUCTION TO BACTERIAL INFECTIONS AND THEIR THERAPY ....................................... 3
1.4.1 Introduction to Bacteria and Bacterial Infections............................................................................ 3
1.4.2 Bacterial Groups .............................................................................................................................. 4
1.5 GLOSSARY OF TERMS ......................................................................................................................... 12
Section 2 DELPHI PANEL AND THOUGHT LEADER INTERVIEW: DISCUSSION AND SUMMARY OF
ANTIBACTERIAL THERAPEUTICS INNOVATION........................................................... 17
2.1 INTRODUCTION .................................................................................................................................... 17
2.2 RESULTS OF DELPHI PANEL INTERVIEWS..................................................................................... 17
Common and Important Pathogenic Bacteria ..................................................................................................................17
Emerging Bacterial Infections .........................................................................................................................................20
Bacteriological Warfare...................................................................................................................................................22
Antibiotics and Antibiotic Resistance .............................................................................................................................23
Vaccines ..........................................................................................................................................................................28
Other Future Developments.............................................................................................................................................30
2.3 DELPHI SUMMARY............................................................................................................................... 33
Section 3 BACTERIAL INFECTIONS BY THERAPEUTIC AREA.................................................................. 35
3.1 RESPIRATORY TRACT INFECTIONS ................................................................................................. 35
3.1.1 Diseases Involved ........................................................................................................................... 35
3.1.2 Current and Likely Future Treatments........................................................................................... 36
3.1.3 Market Analysis............................................................................................................................. 37
3.2 GENITOURINARY TRACT INFECTIONS ........................................................................................... 40
3.2.1 Diseases Involved ........................................................................................................................... 40
3.2.2 Current and Likely Future Treatments........................................................................................... 40
3.2.3 Market Analysis............................................................................................................................. 41
3.3 GASTROINTESTINAL TRACT INFECTIONS ..................................................................................... 43
3.3.1 Diseases Involved ........................................................................................................................... 43
3.3.2 Current and Likely Future Treatments........................................................................................... 44
3.3.3 Market Analysis............................................................................................................................. 45
3.4 SKIN AND SOFT TISSUE INFECTIONS .............................................................................................. 47
3.4.1 Diseases Involved ........................................................................................................................... 47
3.4.2 Current and Likely Future Treatments........................................................................................... 47
3.4.3 Market Analysis............................................................................................................................. 47
3.5 OTHER INFECTIONS............................................................................................................................. 50
3.5.1 Central Nervous System Infections................................................................................................. 50
3.5.2 Intra-abdominal infections ............................................................................................................. 51
3.5.3 Ear infections ................................................................................................................................ 51
3.5.4 Bacteremia and Septicemia ............................................................................................................ 51
3.5.5 Bone and Joint Infections ............................................................................................................... 51
3.5.6 Stomatological Infections ............................................................................................................... 51
Section 4 ANTIBIOTICS......................................................................................................................................... 53
4.1 INTRODUCTION TO ANTIBIOTICS .................................................................................................... 53
v
4.2 MECHANISMS OF ANTIBIOTIC ACTION .......................................................................................... 53
4.2.1 Inhibition of Cell Wall Synthesis .................................................................................................... 53
4.2.2 Disruption of Cell Membrane Structure......................................................................................... 53
4.2.3 Inhibition of Protein Synthesis ....................................................................................................... 54
4.2.4 Inhibition of DNA Transcription .................................................................................................... 54
4.3 CLASSES OF ANTIBIOTICS.................................................................................................................. 54
4.3.1 Penicillins, Cephalosporins, and Other Beta-Lactams .................................................................. 54
Overview.........................................................................................................................................................................54
Utility ..............................................................................................................................................................................55
Strengths and Weaknesses...............................................................................................................................................55
Noteworthy Developments..............................................................................................................................................56
Forecast ...........................................................................................................................................................................57
4.3.2 Aminoglycosides............................................................................................................................ 57
Overview.........................................................................................................................................................................57
Utility ..............................................................................................................................................................................58
Strengths and Weaknesses...............................................................................................................................................58
Noteworthy Developments..............................................................................................................................................58
Forecast ...........................................................................................................................................................................59
4.3.3 Tetracyclines ................................................................................................................................. 59
Overview.........................................................................................................................................................................59
Utility ..............................................................................................................................................................................60
Strengths and Weaknesses...............................................................................................................................................60
Noteworthy Developments..............................................................................................................................................60
Forecast ...........................................................................................................................................................................61
4.3.4 Macrolides..................................................................................................................................... 61
Overview.........................................................................................................................................................................61
Utility ..............................................................................................................................................................................61
Strengths and Weaknesses...............................................................................................................................................62
Noteworthy Developments..............................................................................................................................................62
Forecast ...........................................................................................................................................................................63
4.3.5 Streptogramins ............................................................................................................................... 63
Overview.........................................................................................................................................................................63
Utility ..............................................................................................................................................................................63
Strengths and Weaknesses...............................................................................................................................................64
Noteworthy Developments..............................................................................................................................................64
Forecast ...........................................................................................................................................................................64
4.3.6 Rifamycins ..................................................................................................................................... 65
Overview.........................................................................................................................................................................65
Utility ..............................................................................................................................................................................65
Strengths and Weaknesses...............................................................................................................................................65
Noteworthy Developments..............................................................................................................................................65
Forecast ...........................................................................................................................................................................65
4.3.7 Glycopeptides and Other Peptide Antibiotics................................................................................. 65
Overview.........................................................................................................................................................................65
Utility ..............................................................................................................................................................................66
Strengths and Weaknesses...............................................................................................................................................66
Noteworthy Developments..............................................................................................................................................66
Forecast ...........................................................................................................................................................................69
4.3.8 Quinolones .................................................................................................................................... 69
Overview.........................................................................................................................................................................69
Utility ..............................................................................................................................................................................70
Strengths and Weaknesses...............................................................................................................................................70
Noteworthy Developments..............................................................................................................................................71
Forecast ...........................................................................................................................................................................73
4.3.9 Oxazolidinones ............................................................................................................................... 74
4.3.10 Other Antibiotics ............................................................................................................................ 75
Overview.........................................................................................................................................................................75
Utility ..............................................................................................................................................................................75
Strengths and Weaknesses...............................................................................................................................................75
Noteworthy Developments..............................................................................................................................................75
vi
Forecast ...........................................................................................................................................................................76
4.4 MECHANISMS OF ANTIBIOTIC RESISTANCE ................................................................................. 76
4.4.1 Antibiotic Inactivation................................................................................................................... 76
4.4.2 Antibiotic Entry and Efflux............................................................................................................. 76
4.4.3 Mutation of the Antibiotic Target Site ............................................................................................ 76
4.4.4 Alternative Metabolic Pathways..................................................................................................... 77
Section 5 TECHNOLOGY PLATFORMS OTHER THAN ANTIBIOTICS...................................................... 79
5.1 OTHER LOW-MOLECULAR-WEIGHT THERAPEUTICS.................................................................. 79
5.1.1 Trimethoprim and Sulfonamides .................................................................................................... 79
Overview.........................................................................................................................................................................79
Utility ..............................................................................................................................................................................79
Strengths and Weaknesses...............................................................................................................................................79
Noteworthy Developments..............................................................................................................................................80
Forecast ...........................................................................................................................................................................80
5.1.2 Metronidazole................................................................................................................................ 80
5.1.3 Nitrofurantoin and Other Nitrofurans............................................................................................ 80
5.2 VACCINES AND IMMUNOTHERAPIES.............................................................................................. 80
5.2.1 Vaccines ........................................................................................................................................ 80
Overview.........................................................................................................................................................................80
Utility ..............................................................................................................................................................................82
Strengths and Weaknesses...............................................................................................................................................82
Noteworthy Developments..............................................................................................................................................82
Forecast ...........................................................................................................................................................................86
5.2.2 Antibodies...................................................................................................................................... 86
5.2.3 Other Immunotherapies................................................................................................................. 87
5.3 OTHER TECHNOLOGIES...................................................................................................................... 88
Overview.........................................................................................................................................................................88
Noteworthy Development ...............................................................................................................................................88
Section 6 OVERALL ANALYSIS AND FORECAST FOR ANTIBACTERIALS ............................................. 89
6.1 PRODUCT TECHNOLOGY ANALYSIS AND FORECAST ................................................................ 89
6.2 MARKET ANALYSIS AND FORECAST ............................................................................................ 104
6.3 EVALUATION OF LICENSING OPPORTUNITIES – RATINGS AND RANKINGS....................... 107
Section 7 COMPANY PROFILES OF INNOVATIVE FIRMS REPRESENTING ACQUISITIONS,
LICENSING, AND COMARKETING OPPORTUNITIES IN ANTIBACTERIAL
THERAPY ................................................................................................................................. 121
7.1 ACAMBIS .............................................................................................................................................. 121
7.2 ANTEX BIOLOGICS............................................................................................................................. 122
7.3 ANTIGENICS......................................................................................................................................... 122
7.4 AVANT IMMUNOTHERAPEUTICS ................................................................................................... 123
7.5 AXCAN PHARMA ................................................................................................................................ 123
7.6 CSL ...................................................................................................................................................... 124
7.7 CUBIST PHARMACEUTICALS........................................................................................................... 124
7.8 DAIICHI SEIYAKU............................................................................................................................... 125
7.9 DEMEGEN............................................................................................................................................. 126
7.10 ESSENTIAL THERAPEUTICS............................................................................................................. 126
7.11 GENOME THERAPEUTICS ................................................................................................................. 127
7.12 ID BIOMEDICAL CORPORATION ..................................................................................................... 127
7.13 INCYTE GENOMICS ............................................................................................................................ 128
7.14 INTERMUNE......................................................................................................................................... 129
7.15 INTRABIOTICS..................................................................................................................................... 130
7.16 LIGOCYTE PHARMACEUTICALS..................................................................................................... 130
7.17 MEDIMMUNE....................................................................................................................................... 131
7.18 MEIJI SEIKA.......................................................................................................................................... 131
7.19 MICROLOGIX BIOTECH..................................................................................................................... 132
vii
7.20 NABI ...................................................................................................................................................... 132
7.21 NEOSE TECHNOLOGIES .................................................................................................................... 133
7.22 NEWBIOTICS........................................................................................................................................ 133
7.23 NIPPON MEDICAL RESEARCH ......................................................................................................... 134
7.24 POWDERJECT PHARMACEUTICALS............................................................................................... 134
7.25 SEQUELLA............................................................................................................................................ 134
7.26 SHIONOGI ............................................................................................................................................. 135
7.27 SHIRE PHARMACEUTICALS GROUP............................................................................................... 136
7.28 SIGA TECHNOLOGIES........................................................................................................................ 136
7.29 TAIHO PHARMACEUTICAL COMPANY.......................................................................................... 137
7.30 TAKEDA CHEMICAL INDUSTRIES .................................................................................................. 137
7.31 TOYAMA CHEMICAL CO................................................................................................................... 137
7.32 VERSICOR............................................................................................................................................. 138
7.33 VICAL .................................................................................................................................................... 138
7.34 WAKUNAGA PHARMACEUTICAL CO............................................................................................. 139
7.35 XOMA .................................................................................................................................................... 139 |
|
|
Ordering: |
Order Online - visit http://www.researchandmarkets.com/reports/1317
Order by Fax - using the order form below
Order By Post - print the order form below and send to
|
|
Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
|
|
|
 |
Page 1 of 2
Printed 30/08/2008 14:26:58 |
|
Fax Order Form
To place an order via fax simply print this form, fill in the information below and
fax the completed form to the number at the bottom of this page. If you have any questions please email help@researchandmarkets.com
Order information
Please verify that the product information is correct and select the format you require.
|
|
|
|
Product Name: |
Antibacterial Drug Licensing Opportunities: Analysis, Rating, and Ranking - A Worldwide Study
|
|
Web Address: |
http://www.researchandmarkets.com/reports/1317
|
|
Office Code: |
|
OCHGMLITUXV
|
Report formats
Please enter the quantity of the report format you require.
|
|
Format
|
Quantity
|
Price
|
|
Hard Copy
|
|
€10,433.00 + EUR€ 50.00 Shipping/Handling *
|
* Shipping/Handling is only charged once per order.
Contact information
Please enter all the information below in BLOCK CAPITALS.
|
|
|
First Name: |
Last Name: |
|
Email Address: |
|
|
Job Title: |
|
|
Organisation: |
|
|
Address: |
|
|
City: |
|
|
Postal/Zip Code: |
|
|
Country: |
|
|
Phone Number: |
|
|
Fax Number: |
|
|
Please fax this form to:
(646)607-1907 or (646)964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World
|
|
Page 2 of 2
Printed 30/08/2008 14:26:58
|
|
Payment information
Please indicate the payment method you would like to use by selecting the appropriate
box.
|
|
|
|
|
American Express
|
|
|
Diners Club
|
|
|
Master Card
|
|
|
Visa
|
|
|
|
|
|
|
Cardholder Name: |
|
|
|
|
Expiry Date: |
/ |
|
|
|
Card Number: |
|
|
|
|
CVV Security Code: |
|
|
|
|
Issue Date: |
/ (Diners
Club only)
|
|
|
|
|
|
|
Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
|
|
|
|
|
|
|
Please transfer funds to:
|
|
|
Account number: |
83313083 |
|
Sort code: |
98-53-30 |
|
Swift code: |
ULSBIE2D |
|
IBAN number: |
IE78ULSB98533083313083 |
|
Bank Address: |
Ulster Bank,
27-35 Main St,
Blackrock,
Co. Dublin,
Ireland. |
|
|
|
If you have a Marketing Code please enter it below:
|
|
|
Marketing Code: |
|
|
Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp
|
|
Please fax this form to:
(646)607-1907 or (646)964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World
|
|
|
|
|
|
